PSG announces the results of its extensive research on the latest trends in specialty drug benefits. This exclusive research offers comprehensive insights to assist employers,…
Rethinking What “Data-Driven Strategy” Means in Pharmacy Benefits Key Points Many leaders use data to validate strategy, but the greatest value emerges when analytics become…
An Overview of Regulatory and Legislative Updates For Plan Sponsors Key Points The ESI settlement creates new options for plan sponsors, but few protections apply…
Will Additional SMA Gene Therapies Affect Payers’ Budgets? Key Points: SMA treatment has shifted from supportive care to high-cost disease-modifying and gene therapies, with lifetime…
What Does TrumpRx Mean For Payers? Key Points TrumpRx launched February 5, 2026, offering cash-pay pricing for 43 drugs outside of insurance, with no eligibility…
Quickly Identify Inappropriate Concurrent Use with Artemetrx Data and Analytics Key Points: Inappropriate concurrent medication use can drive unnecessary cost and increase safety risks, especially…
How Payer Feedback Can Help Improve the Pharmacy Benefit Management Industry As pharmacy benefit management continues to evolve, the latest findings from the 2025…
